Predict your next investment

Cellusion company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series A | Alive

Total Raised


Last Raised

$3.27M | 1 yr ago

About Cellusion

Cellusion is a healthcare company that specializes in the R&D, manufacturing, and sales of induced pluripotent stem cell-derived corneal endothelial cells for bullous keratopathy therapy. The company's technology allows the medical community to safely treat patients with minimally invasive cell therapy, and solve not only the donor shortage issue, but also reduce surgery time and the risk of complications.

Cellusion Headquarter Location

2-4-15 Minamiaoyama Minato City

Tokyo, 107-0062,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cellusion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cellusion is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,670 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



5,821 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.